ePrivacy and GPDR Cookie Consent by TermsFeed Generator
Request a Quote

Search

Spotlight Theater | From Genomic Insights to Clinical Solutions: The Role of 3D Genomics in Cancer Research and Diagnostics

Monday, April 8, 2024 | 10:00 am – 11:00 am
Spotlight Theater E

3D genomic technologies enable scientists and clinical researchers to uncover novel disease mechanisms, identify new therapeutic targets, and identify gene fusions. Discover the future of cancer diagnostics at the Arima Genomics Spotlight Theater, where you’ll gain insights from leading experts on how 3D genomics technology is setting a new standard in cancer diagnostics, from detailed genomic analysis to practical clinical applications.

 

What You Will Learn

  1. Pushing the Boundaries of Cancer Research with 3D Genomics: Learn about the application of 3D genomics in glioblastoma research from Dr. Feng Yue of Northwestern University, highlighting the impact of 3D genomics in unraveling cancer complexities in one of the most difficult-to-treat brain tumors.
  2. Technical Foundations and Future Directions: Dive into the science behind 3D genomics with Dr. Anthony Schmitt of Arima Genomics, understanding its role in advancing oncology research and its implications for the future of oncology research.
  3. New Advancements in Cancer Diagnostics: Discover how Arima’s innovative clinical testing service, through our partnership with Aventa Genomics, is pioneering the way for more accessible and precise cancer diagnostics.

Save Your Seat

Meet the Speakers

Anthony Schmitt, PhD

Arima Genomics

Dr. Anthony Schmitt is the SVP of Science at Arima Genomics, where his expertise in 3D genomics has been pivotal to the company's development of Hi-C technology and its applications in genomics research. He received his PhD from the University of California, San Diego, where he developed novel methodologies for understanding gene regulation using 3D genomics approaches. Since Arima’s inception, Dr. Schmitt has led the development of the core Arima Hi-C chemistry and technology platform, as well as industry partnerships and academic collaborations.

Feng Yue, PhD

Northwestern University

Dr. Feng Yue is the director of the Center for Cancer Genomics at Northwestern University's Lurie Cancer Center and the Center for Advanced Molecular Analysis. He is also the Duane and Susan Burnham Professor of Molecular Medicine and a professor of Biochemistry, Molecular Genetics, and Pathology. His research focuses on epigenomics and 3D genome organization in human diseases. A prominent member of NIH-funded projects like ENCODE and the 4D Nucleome Project, Dr. Yue's work has pioneered the use of Hi-C for discovering structural variations in cancer genomes, aiming to identify key biomarkers and therapeutic targets specific to cancer subtypes.

Stop by our Poster Session

Validation of Aventa FusionPlus: An LDT NGS assay for comprehensive cancer genomic profiling

Presentation Number: 325 / 13

Sunday, April 7 | 1:30 pm – 5:00 pm
Poster Section 14 | Poster Board #13

Next-generation sequencing (NGS) assays play a pivotal role in illuminating the genomic landscape of cancer by providing insights into gene regulation and biomarker detection for the purpose of guiding therapeutic decisions to advance personalized medicine. We validated the Aventa FusionPlus Test, a Laboratory-Developed Test (LDT) that integrates HiC technology to enhance detection of actionable gene fusions and rearrangements in solid tumors, including those that are missed by current standard of care tests. This is a DNA-based test that is robust to DNA degradation in FFPE specimens, in contrast with RNA-seq and long-read technologies. The test utilizes the Element Biosciences AVITI sequencing platform to achieve high quality sequencing data at low cost per sample. – View more in the AACR 2024 Itinerary Planner.